FierceBiotech3d
Aviceda raises $207M series C to take geographic atrophy drug through phase 3
Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...
Three simple ways to look after your eyes
As we think about how to prioritise our health this January, we should be aware of the importance of eye health. Dr Paramdeep ...